Drug Trial Radar · NCT06943521
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
27
Planned (sponsor's estimate)
Start
Apr 18, 2025
Primary completion
Aug 2028
Study completion Aug 2028
Sponsor
- Lead sponsor
- Tanabe Pharma America, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerability, PK and pharmacodynamics of MT-4561 and determining the Maximum Tolerated Dose (MTD) using the Bayesian Optimal Interval (BOIN) design. The study details and doses of Part 2 (dose-optimization) and Part 3 (Drug-Drug Interaction) will be available after review of applicable Part 1 results.
Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Non-small Cell Lung Cancer (NSCLC)
- Esophageal Cancer
- Gastric Cancer
- Biliary Tract Cancer
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Breast Cancer
- Ovarian Cancer
- Cervical Cancer
- Endometrial Cancer
- Prostate Cancer
- Urothelial Carcinoma
- Neuroendocrine Tumor (NET)
- Neuroendocrine Carcinoma (NEC)
- Soft Tissue Sarcoma
- Nuclear Protein in Testis (NUT) Carcinoma
Interventions
MT-4561Drug
i.v.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Event, Dose limiting toxicities (DLTs)Time frame: a 28-day cycle
- Number of Patients with Adverse events (AEs)Time frame: Screening through 30 days after last dose
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
University of Southern California
Los Angeles, California · Recruiting
START Midwest
Grand Rapids, Michigan · Recruiting
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
National Cancer Center Hospital East
City, Japan · Recruiting
National Cancer Center Hospital
Chuo-Ku, Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.